OTC: TLPPF - Telix Pharmaceuticals Limited

半年間の収益性: +33.31%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Telix Pharmaceuticals Limited

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR.

さらに詳しく
Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://telixpharma.com
Цена ао 19.02
1日あたりの価格変動: 0% (19.05)
週ごとの価格変動: +5.78% (18.009)
月ごとの料金変更: -1.04% (19.25)
3ヶ月間の価格変動: +23.54% (15.42)
半年間の価格変動: +33.31% (14.29)
年間の価格変動: +125.44% (8.45)
3年間の価格推移: +390.98% (3.88)
5年間の価格推移: +2 089.66% (0.87)
年初からの価格変動: +21.26% (15.71)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 10.34 1
P/BV 14.26 1
P/E 162.28 1
EV/EBITDA 51.61 1
合計: 2.13

効率

名前 意味 学年
ROA, % 4.75 1
ROE, % 12.69 4
合計: 2.17

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA 8.9 0
合計: 5.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 12525.64 10
収益性 Ebitda, % -164.29 0
収益性 EPS, % -164.47 0
合計: 2
さらに詳しく

機関 音量 共有, %
Vanguard International Stock Index-Total Intl Stock Indx 2270925 0.7
iShares Core MSCI EAFE ETF 1376002 0.42
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1343237 0.41
College Retirement Equities Fund-Stock Account 937783 0.29
iShares MSCI EAFE Small Cap ETF 923323 0.28
TIAA-CREF Funds-Quant International Small Cap Equity Fund 706384 0.22
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 619774 0.19
SPDR Portfolio Developed World ex-US ETF 468831 0.14
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 323859 0.1
iShares Core MSCI Total International Stock ETF 312675 0.1



スーパーバイザー 役職 支払い 生年
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 379.52k 1965 (60 年)
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Non-Executive Director 28.57k 1965 (60 年)
Mr. Richard Valeix M.B.A. Chief Executive Officer of Telix Therapeutics 424.25k 1975 (50 年)
Mr. Craig Ulrick Chief Information Officer N/A
Ms. Kyahn Williamson B.A. Senior Vice President of Corporate Communications & Investor Relations N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Senior Vice President of Global Governance, Risk & Compliance N/A
Mr. Darren Patti Group Chief Operating Officer N/A 1972 (53 年)
Dr. David N. Cade M.B.A., M.D., MBBS Group Chief Medical Officer N/A 1969 (56 年)
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, MD, Group CEO & Executive Director 1976 (49 年)
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist

住所: Australia, North Melbourne. VIC, 55 Flemington Road - Googleマップで開く, Yandexマップを開く
Webサイト: https://telixpharma.com